From the Guidelines
Microbacterium species are typically susceptible to a range of antibiotics. For treatment of infections caused by Microbacterium species, vancomycin is recommended at a dose of 1 gram every 12 hours, with a duration of treatment ranging from 7 to 14 days depending on the severity and site of infection 1. Alternative regimens may include cefepime at a dose of 2 grams every 8 hours, or gentamicin at a dose of 5 mg/kg daily, with dosing adjustments based on renal function and clinical response.
Key Considerations
- The choice of antibiotic should be based on the severity and site of infection, as well as the patient's clinical response 1.
- Vancomycin is a recommended option for treatment of Microbacterium species, with a dose of 1 gram every 12 hours 1.
- Alternative regimens, such as cefepime and gentamicin, may be considered based on the patient's clinical response and renal function 1.
- The duration of treatment should be individualized based on the patient's clinical response, but typically ranges from 7 to 14 days 1.
Antibiotic Options
- Vancomycin: 1 gram every 12 hours 1
- Cefepime: 2 grams every 8 hours 1
- Gentamicin: 5 mg/kg daily, with dosing adjustments based on renal function and clinical response 1
From the Research
Antibiotic Coverage for Microbacterium
There are no research papers that directly address the antibiotic coverage for Microbacterium. However, we can look at the antibiotic susceptibilities of related species, such as Corynebacterium, to gain some insight.
- The study 2 tested the susceptibilities of 265 strains of Corynebacterium species and other non-spore-forming gram-positive bacilli to 18 antimicrobial agents.
- Most strains were susceptible to vancomycin, doxycycline, and fusidic acid.
- However, resistance to beta-lactams, clindamycin, erythromycin, azithromycin, ciprofloxacin, and gentamicin was common among strains of Corynebacterium xerosis and Corynebacterium minutissimum.
- The study 3 analyzed the genetic potential of 70 Microbacterium species, but did not provide information on antibiotic susceptibilities.
Related Antibiotic Studies
While not directly related to Microbacterium, other studies provide information on antibiotic coverage for related species or broad-spectrum antibiotics:
- The study 4 reviewed the use of ceftobiprole, a broad-spectrum cephalosporin, against Gram-positive cocci, including MRSA, and Gram-negative bacilli.
- The study 5 compared the use of high-dose cefepime and carbapenems for bacteremia caused by Enterobacterales with moderate to high risk of clinically significant AmpC β-lactamase production.
- The study 6 reviewed the use of levofloxacin, a fluoroquinolone antibacterial agent, against a range of Gram-positive and Gram-negative bacteria and atypical organisms.